<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02232542</url>
  </required_header>
  <id_info>
    <org_study_id>1208.1</org_study_id>
    <nct_id>NCT02232542</nct_id>
  </id_info>
  <brief_title>Tolerability and Safety of Duloxetine BID in Healthy Female Subjects</brief_title>
  <official_title>Tolerability and Safety of 40 mg and 100 mg Duloxetine BID Given Over 7 Days in Healthy Female Subjects. A Randomised, Placebo-controlled Double-blind Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Study to assess the safety and tolerability of 100 mg of duloxetine BID compared to 40 mg of
      duloxetine BID or placebo for 7 days
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2003</start_date>
  <primary_completion_date type="Actual">August 2003</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of tolerability by investigator on a 4-point scale</measure>
    <time_frame>Up to day 14 after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with adverse events</measure>
    <time_frame>Up to day 14 after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with clinically relevant findings in electrocardiogram (ECG)</measure>
    <time_frame>Up to day 14 after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with clinically relevant findings in vital signs</measure>
    <time_frame>Up to day 14 after drug administration</time_frame>
    <description>systolic and diastolic blood pressure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with abnormal changes in laboratory parameters</measure>
    <time_frame>Up to day 14 after drug administration</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Duloxetine - low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Duloxetine - high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Duloxetine - low dose</intervention_name>
    <arm_group_label>Duloxetine - low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Duloxetine - high dose</intervention_name>
    <arm_group_label>Duloxetine - high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy female subjects as determined by results of screening

          -  Signed written informed consent in accordance with Good Clinical Practice (GCP) and
             local legislation

          -  Age ≥ 40 years

          -  BMI ≥ 18.5 and ≤ 29.9 kg/m2

        Exclusion Criteria:

          -  Any finding at any of the medical examinations (including blood pressure, pulse rate
             and ECG (electrocardiogram)) deviating from normal and of clinical relevance (resting
             heart rate greater than 100 bpm or tachyarrhythmia)

          -  History of or current gastrointestinal, hepatic, renal, respiratory, cardiovascular,
             metabolic, immunologic, hormonal disorders (except thyroid hormones and hormonal
             replacement therapy)

          -  History of relevant orthostatic hypotension, fainting spells and blackouts

          -  Diseases of the central nervous system (such as epilepsy) or psychiatric disorders

          -  Chronic or relevant acute infections

          -  History of allergy/hypersensitivity (including drug allergy) which is deemed relevant
             to the trial as judged by the investigator, any bleeding disorder including prolonged
             or habitual bleeding, other hematologic disease, cerebral bleeding (e.g. after a car
             accident), commotio cerebri

          -  Intake of drugs with a long half-life (&gt; 24 hours) within 1 month prior to
             administration

          -  Use of any drugs that might influence the results of the trial (especially CYP2D6 or
             CYP1A2 modulating substances) within 2 weeks prior to administration or during the
             trial

          -  Participation in another trial with an investigational drug within 2 months prior to
             administration or during trial

          -  Smoker (&gt; 10 cigarettes or 3 cigars or 3 pipes/day) or inability to refrain from
             smoking on study days

          -  Alcohol abuse (&gt; 60 g/day)

          -  Caffeine abuse (&gt; 4 cups/day)

          -  Drug abuse

          -  Blood donation within 1 month prior to administration or during the trial

          -  Excessive physical activities within 10 days prior to administration or during the
             trial

          -  Any laboratory value outside the clinically accepted reference range

          -  Ineffective contraception
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
  </link>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 4, 2014</study_first_submitted>
  <study_first_submitted_qc>September 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 5, 2014</study_first_posted>
  <last_update_submitted>September 4, 2014</last_update_submitted>
  <last_update_submitted_qc>September 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 5, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Duloxetine Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

